Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918976 | 0.89 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13973185 | 0.86 | CD44 (0.36) | CD44CYP3A4RAPGEF4PTGS2GPR3 | |
| SCHEMBL7062222 | 0.86 | CD44 (0.48) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL762587 | 0.83 | KDM1A (0.39) | CD44CYP3A4LMNARAPGEF4SMN1; SMN2 | |
| SCHEMBL11043190 | 0.83 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10147311 | 0.78 | ACHE (0.40) | CYP3A4RAPGEF4GPR3ACHE | |
| SCHEMBL8261003 | 0.78 | CD44 (0.58) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7550920 | 0.78 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6951667 | 0.78 | RAPGEF4 (0.38) | CD44CYP3A4LMNARAPGEF4SMN1; SMN2 | |
| SCHEMBL18617511 | 0.77 | LMNA (0.52) | CD44GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137813-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138211-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| EP-2930170-B1 | PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3169662-B1 | SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2018-07-11 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-7479531-B2 | Copolymer of ethylene and/or propylene; and octen-1-ol,7-octen-1-ol trimethylsilyl ether, octenyl acetate, 5-norbornen-2-yl acetate, 5-norbornen-2-ol and/or 5-norbornen-2-ol trimethylsilyl ether; transition metal catalyst comprising 2-arylazo- or 2-arylphosphazo- phenoxide ligand | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479531-B2 | Copolymer of ethylene and/or propylene; and octen-1-ol,7-octen-1-ol trimethylsilyl ether, octenyl acetate, 5-norbornen-2-yl acetate, 5-norbornen-2-ol and/or 5-norbornen-2-ol trimethylsilyl ether; transition metal catalyst comprising 2-arylazo- or 2-arylphosphazo- phenoxide ligand | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7285609-B2 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285609-B2 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1626976-B1 | OLEFIN POLYMERIZATION CATALYST SYSTEM | EXXONMOBIL CHEM PATENTS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1626999-B1 | OLEFIN POLYMERIZATION CATALYST SYSTEM USEFUL FOR POLAR MONOMERS | EXXONMOBIL CHEM PATENTS INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070197751-A1 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197751-A1 | Olefin polymerization catalyst system useful for polar monomers | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CD44 741/4885GRIN2D 1379/4885GRIN3B 506/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | CD44 741/4885GRIN2D 1379/4885GRIN3B 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.